ClinicalTrials.gg
RecruitingNCT02823665Updated Sep 9, 2025

The Effects of Bariatric Surgeries on Glucose Metabolism

An Early Phase 1 interventional study of Exendin-(9-39) and Atropine in Post Bariatric Surgery, Gastric Bypass and Sleeve Gastrectomy, sponsored by The University of Texas Health Science Center at San Antonio. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by The University of Texas Health Science Center at San Antonio · Early Phase 1, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing avexitide in Hypoglycemia — 3 open to participants now, 4 under way, 1 of them phase 3. avexitide · Hypoglycemia.

Planned enrollment
Largest of 12
200 · median 18
Started
2015
the only one that year
Phase 1
4 of 12
3 open now
Registered
8th of 12
by date
Lead sponsor
3 of 12
The University of Texas Health Science Center at San Antonio

Among the 12 studies testing avexitide in Hypoglycemia, this one has the largest planned enrollment, is the only one that started in 2015, is one of 4 in phase 1, and was the 8th registered.

Hypoglycemia

706 studies on the registry are indexed under Hypoglycemia; 94 are open to participants now.

Browse Hypoglycemia studies →

Open to participants now

3 of the 12 studies testing avexitide in Hypoglycemia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About avexitide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 59 Hypoglycemia studies recruiting now, 23 (39%) set no upper age limit and 31 (53%) stop at 75 or younger; 18 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing avexitide in Hypoglycemia, or all of them as a file.
02

Study summary

The purpose of this study is learn the effect of gastric bypass surgery and sleeve gastrectomy on glucose metabolism mediated by neural and hormonal factors initiated after eating.

Read the detailed description

The purpose of this study is to determine the weight-independent effects of gastric bypass surgery and sleeve gastrectomy surgery on islet cell response after meal ingestion as mediated by hormonal and neural components of the gut. It will also address the differences between the two procedures.

Such information will be critical for the development of novel approaches for treatment of diabetes as well as improvement of glycemic effects of gastric bypass and sleeve gastrectomy in patients with partial diabetes remission or relapse after complete remission.

03

Conditions studied

  • Post Bariatric Surgery
  • Gastric Bypass
  • Sleeve Gastrectomy
  • Hypoglycemia After Gastric Bypass

Browse trials for

Keywords

  • gastric bypass surgery
  • Hypoglycemia
  • sleeve gastrectomy
  • glucose tolerance
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hypoglycemic RYGB patients with documented blood glucose level \<50 mg/dl
  • Asymptomatic individuals with bariatric surgery
  • Healthy non-surgical patients with no personal history of diabetes
  • Subjects must physically be able to come to our clinical research center Cedars-Sinai Medical Center

Exclusion criteria

Exclusion Criteria:

  • Active heart, lung, liver, gastrointestinal or kidney disease; unable to give ; pregnancy; uncontrolled high blood pressure or high cholesterol; significant anemia ( \<11g/dL); prisoners or institutionalized individuals; type 2 diabetes mellitis; development of any serious medical or psychiatric illness during recruitment or studies;
  • RYGB patients will be disqualified if they have gastric outlet obstruction or severe diarrhea.
  • Healthy non-surgical patients with personal history of diabetes

For administration of atropine, the following exclusions also apply:

  • History of glaucoma
  • Uncontrolled hypertension (any subjects with BP>140/90 and history of dyslipidemia
  • Taking any medication that might interact with atropine and cannot be stopped will be excluded from the study)
  • Myasthenia gravis
  • Brain pathology
  • Enlarged prostate in men
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Early Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Exendin-(9-39)

    To evaluate the role of GLP-1 on glucose metabolism and insulin secretin after glucose and protein ingestion.

    Drug: Exendin-(9-39)

  • Experimental
    Atropine

    to evaluate the effect of neural activation on insulin secretion and glucose metabolism

    Drug: Atropine

Interventions

  • DrugAvexitideStudies of AvexitideAvexitide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A physiological study to evaluate the role of GLP-1 on glucose metabolism and insulin secretin after glucose and protein ingestion.

    Also known as: no other name for Exendin-(9-39)

  • A physiological study to evaluate the effect of neural activation on insulin secretion and glucose metabolism.

    Also known as: Atropine sulfate

06

What researchers measure

Primary outcomes

  1. Insulin levels measured after nutrient ingestion

    Time frame: Each study in the protocol is conducted up to seven hours with data collected at intervals specific to the individual study procedure.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2015, a primary completion of Aug 2026 and a completion of Aug 2027. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2015
First posted
Jul 6, 2016
Start
Jul 2015
Primary completionEst.
Aug 2026
CompletionEst.
Aug 2027
Last update
Sep 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02823665
Responsible party
Sponsor
First posted
Jul 6, 2016
Start date
Jul 2015
Primary completion
Aug 2026 (estimated)
Completion
Aug 2027 (estimated)
Last update
Sep 9, 2025

Study contacts

Marzieh Salehi, MD MS
Contact
salehi@uthscsa.edu
210-567-6691
Jennifer Foster, MSN
Contact
fosterj6@uthscsa.edu
210-450-8696
Marzieh Salehi, MD, MS
principal investigator · The University of Texas Health Science Center at San Antonio

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Avexitide · Atropine

Start the discussion